Am J Transplant, Volume 3, Suppl 5 Archives - Page 154 of 178 - ATC Abstracts

2013 American Transplant Congress
Assessment of the Time to Therapeutic Tacrolimus Levels and the Incidence of Rejection in Heart Transplant Patients
M. Moaddab, L. Simpson, M. Rabourn
St.Luke's Episcopal Hospital, Houston, TX; Texas Heart Institute, Houston, TX
Purpose: To assess the relationship between the time to achieve consecutive therapeutic tacrolimus levels and the incidence of rejection to optimize tacrolimus dosing in cardiac…
2013 American Transplant Congress
Elevated Tacrolimus Trough Concentrations Significantly Increase the Risk of New Onset Diabetes after Liver Transplantation
R. Amarnath, D. Taber, N. Pilch, H. Meadows, J. Fleming, A. Mardis, K. Morbitzer, C. Jordan, C. Makowski, C. Bratton, J. McGillicuddy, P. Baliga, K. Chavin
Transplant Surgery, Medical University of South Carolina, Charleston, SC
Background: Tacrolimus (FK) is the most common CNI used following liver transplantation (LTx). FK is highly effective at preventing rejection, but is associated with numerous…
2013 American Transplant Congress
Thymoglobulin Is Safe and Effective as Induction Therapy for Early Steroid Withdrawal in Pediatric Renal Transplantation
J. Kim, A. Watkins, M. Aull, J. Guerrero, S. Kapur
Surgery, NewYork-Presbyterian/Weill Cornell Medical Center, New York, NY
Introduction:Early steroid withdrawal (SW) for maintenance immunosuppression has been gaining acceptance in pediatric kidney transplant recipients. Despite its use in adult renal transplants, data on…
2013 American Transplant Congress
IL-2 Antagonist Induction Therapy Preserves Renal Function in Liver Transplant Recipients
A. Mardis, H. Meadows, D. Taber, N. Pilch, J. Fleming, C. Jordan, K. Morbitzer, C. Makowski, J. McGillicuddy, C. Bratton, K. Chavin, P. Baliga
Pharmacy, MUSC, Charleston, SC; Transplant, MUSC, Charleston, SC
Background: Studies have produced varying results regarding whether IL-2 antagonist induction improves outcomes, including renal function and patient and graft survival in liver transplantation. This…
2013 American Transplant Congress
NASH Recurrence: Focus on Preventing New Onset Diabetes?
C. Jordan, N. Pilch, D. Taber, H. Meadows, J. Fleming, A. Mardis, K. Morbitzer, C. Makowski, J. McGillicuddy, C. Bratton, A. Lin, P. Baliga, K. Chavin
Pharmacy, MUSC, Charleston, SC; Transplant, MUSC, Charleston, SC
Background: The aim of this study was to evaluate the risk factors and associated outcomes with NASH recurrence following liver transplant.Methods: Single center retrospective longitudinal…
2013 American Transplant Congress
Ciprofloxacin Combined with SMZ/TMP Prophylaxis Reduces the Incidence of UTIs Following Kidney Transplantation
D. Wojciechowski, S. Chandran
UCSF, San Francisco; UCSF, San Francisco
Introduction:Urinary tract infections (UTIs) are major causes of morbidity and recurrent hospitalizations following kidney transplantation. To date there are no guidelines on antibiotic prophylaxis for…
2013 American Transplant Congress
Metabolomic Distinctions between Renal Allograft Recipients on Monotherapy Sirolimus or Tacrolimus Maintenance Therapy
S. Kim, Y. Park, J. Cheeseman, A. Mehta, D. Jones, A. Kirk
Emory Transplant Center, Emory University, Atlanta, GA; Clinical Biomarkers Laboratory, Emory University, Atlanta, GA
Background. Sirolimus and Tacrolimus have distinct mechanisms of action with distinct side effect profiles. In order to gain mechanistic insights into the differing effects of…
2013 American Transplant Congress
Antiviral Prophylaxis for HBsAg-Positive Renal Transplant Recipients Treated with Rituximab®
Y. Kim, Y. Han, J. Jung, H. Cho, Y. Lim, S. Park, D. Han
Surgery, Asan Medical Center, Seoul, Republic of Korea; Gastroenterology, Asan Medical Center, Seoul, Republic of Korea; Nephrology, Asan Medical Center, Seoul, Republic of Korea
The risk of Hepatitis B virus (HBV) reactivation under immunosuppressant has been well known. Especially, rituximab® is identified as strong risk factors of HBV reactivation…
2013 American Transplant Congress
Delayed Kidney Graft Function in SPK Recipients Is Associated with Poor Long-Term Outcomes
B. Muth, B. Astor, D. Kaufman, H. Sollinger, R. Hofmann, M. Mohamed, V. Vidyasagar, J. Pirsch, J. Bellingham, J. Odorico, A. Djamali
Department of Medicine, University of Wisconsin, Madison, WI; Department of Surgery, University of Wisconsin, Madison, WI
The association of delayed kidney graft function (DGF) with long-term clinical outcomes in simultaneous pancreas kidney (SPK) transplant recipients is largely unknown. To address this…
2013 American Transplant Congress
Treatment Option in Diabetic End Stage Renal Disease Patients with Potential Living Kidney Donor: PAK vs. SPLK
J. Jung, Y. Kim, Y. Han, Y. Chung, H. Cho, J. Park, D. Han
Department of Surgery, Asan Medical Center, Seoul, Republic of Korea; Department of Endocrinology, Asan Medical Center, Seoul, Republic of Korea
In diabetic patients with end stage renal disease who has a potential living kidney donor, pancreas after living kidney transplantation (PAK) or simultaneous cadaveric pancreas…